Fig. 3

The association between MASLD and major adverse cardiovascular events in different subgroups: age < 30 vs. ≥30 years; male vs. female; non-obese (BMI < 25) vs. obese (BMI ≥ 25). MASLD, metabolic dysfunction-associated steatotic liver disease; HR, hazard ratio; CI, confidence interval; BMI, body mass index.